These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 16030295

  • 1. New checkpoint blockers begin human trials.
    Garber K.
    J Natl Cancer Inst; 2005 Jul 20; 97(14):1026-8. PubMed ID: 16030295
    [No Abstract] [Full Text] [Related]

  • 2. New drugs target hypoxia response in tumors.
    Garber K.
    J Natl Cancer Inst; 2005 Aug 03; 97(15):1112-4. PubMed ID: 16077066
    [No Abstract] [Full Text] [Related]

  • 3. Epothilone D (Kosan/Roche).
    Kolman A.
    Curr Opin Investig Drugs; 2004 Jun 03; 5(6):657-67. PubMed ID: 15242255
    [Abstract] [Full Text] [Related]

  • 4. OSI-461 (OSI).
    Galmarini CM.
    Curr Opin Investig Drugs; 2004 Jun 03; 5(6):648-56. PubMed ID: 15242254
    [Abstract] [Full Text] [Related]

  • 5. [In vitro inhibitory effect of dibenzoxanthene CY-B12 on proliferation of tumor cell lines and its possible mechanisms].
    Pu XX, Jiang GF, Chen Y, Xu ZL, Xian LJ.
    Ai Zheng; 2005 Dec 03; 24(12):1442-7. PubMed ID: 16351789
    [Abstract] [Full Text] [Related]

  • 6. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.
    Skladanowski A, Bozko P, Sabisz M.
    Chem Rev; 2009 Jul 03; 109(7):2951-73. PubMed ID: 19522503
    [No Abstract] [Full Text] [Related]

  • 7. Slow start to phase 0 as researchers debate value.
    Twombly R.
    J Natl Cancer Inst; 2006 Jun 21; 98(12):804-6. PubMed ID: 16788150
    [No Abstract] [Full Text] [Related]

  • 8. Diflomotecan. Ipsen.
    Osheroff N.
    IDrugs; 2004 Mar 21; 7(3):257-63. PubMed ID: 15011101
    [No Abstract] [Full Text] [Related]

  • 9. [Induction of G2 /M phase arrest and apoptosis of MCF-7 cells by novel benzofuran lignan via suppressing cell cycle proteins].
    Yang H, Cai YC, Pang JY, Li YQ, Zeng ZL, Xu ZL, Xian LJ.
    Yao Xue Xue Bao; 2008 Feb 21; 43(2):138-44. PubMed ID: 18507339
    [Abstract] [Full Text] [Related]

  • 10. AE-941 (AEterna).
    Dredge K.
    Curr Opin Investig Drugs; 2004 Jun 21; 5(6):668-77. PubMed ID: 15242256
    [Abstract] [Full Text] [Related]

  • 11. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
    Wiltshire T, Senft J, Wang Y, Konat GW, Wenger SL, Reed E, Wang W.
    Mol Pharmacol; 2007 Apr 21; 71(4):1051-60. PubMed ID: 17229870
    [Abstract] [Full Text] [Related]

  • 12. MS-209 Schering.
    Robert J.
    Curr Opin Investig Drugs; 2004 Dec 21; 5(12):1340-7. PubMed ID: 15648956
    [Abstract] [Full Text] [Related]

  • 13. TG-4010 Transgene.
    Cohen S, Kaufman HL.
    Curr Opin Investig Drugs; 2004 Dec 21; 5(12):1319-28. PubMed ID: 15648954
    [Abstract] [Full Text] [Related]

  • 14. AN-9 (Titan).
    Hobdy E, Murren J.
    Curr Opin Investig Drugs; 2004 Jun 21; 5(6):628-34. PubMed ID: 15242252
    [Abstract] [Full Text] [Related]

  • 15. Activation of both Mos and Cdc25 is required for G2-M transition in perch oocyte.
    Priyadarshini A, Basu D, Navneet AK, Bhattacharya A, Bhattacharya S, Maitra S, Bhattacharya S.
    Mol Reprod Dev; 2009 Mar 21; 76(3):289-300. PubMed ID: 18671273
    [Abstract] [Full Text] [Related]

  • 16. G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers.
    Un F.
    Anticancer Drugs; 2007 Apr 21; 18(4):411-7. PubMed ID: 17351393
    [Abstract] [Full Text] [Related]

  • 17. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ, Dueck A, Sargent DJ.
    Cancer Invest; 2008 Jun 21; 26(5):439-44. PubMed ID: 18568764
    [No Abstract] [Full Text] [Related]

  • 18. Inhibition of the G2 DNA damage checkpoint by oliveroline isolated from Duguetia odorata.
    Brastianos HC, Sturgeon CM, Roberge M, Andersen RJ.
    J Nat Prod; 2007 Feb 21; 70(2):287-8. PubMed ID: 17315964
    [Abstract] [Full Text] [Related]

  • 19. 27th Annual JPMorgan Healthcare Conference--BioCryst and Emergent Biosolutions.
    Croasdell G, Gale S.
    IDrugs; 2009 Mar 21; 12(3):149-51. PubMed ID: 19333891
    [No Abstract] [Full Text] [Related]

  • 20. Cancer drugs. Weighing the risks and benefits.
    Bren L.
    FDA Consum; 2007 Mar 21; 41(1):10-9. PubMed ID: 17342832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.